Literature DB >> 28142228

NOTCH1-Dependent Nitric Oxide Signaling Deficiency in Hypoplastic Left Heart Syndrome Revealed Through Patient-Specific Phenotypes Detected in Bioengineered Cardiogenesis.

Sybil C L Hrstka1,2, Xing Li3,4, Timothy J Nelson2,5,6,7.   

Abstract

Hypoplastic left heart syndrome (HLHS) is a severe congenital heart defect (CHD) attributable to multifactorial molecular underpinnings. Multiple genetic loci have been implicated to increase the risk of disease, yet genotype-phenotype relationships remain poorly defined. Whole genome sequencing complemented by cardiac phenotype from five individuals in an HLHS-affected family enabled the identification of NOTCH1 as a prioritized candidate gene linked to CHD in three individuals with mutant allele burden significantly impairing Notch signaling in the HLHS-affected proband. To better understand a mechanistic basis through which NOTCH1 contributes to heart development, human induced pluripotent stem cells (hiPSCs) were created from the HLHS-affected parent-proband triad and differentiated into cardiovascular cell lineages for molecular characterization. HLHS-affected hiPSCs exhibited a deficiency in Notch signaling pathway components and a diminished capacity to generate hiPSC-cardiomyocytes. Optimization of conditions to procure HLHS-hiPSC-cardiomyocytes led to an approach that compensated for dysregulated nitric oxide (NO)-dependent Notch signaling in the earliest specification stages. Augmentation of HLHS-hiPSCs with small molecules stimulating NO signaling in the first 4 days of differentiation provided a cardiomyocyte yield equivalent to the parental hiPSCs. No discernable differences in calcium dynamics were observed between the bioengineered cardiomyocytes derived from the proband and the parents. We conclude that in vitro modeling with HLHS-hiPSCs bearing NOTCH1 mutations facilitated the discovery of a NO-dependent signaling component essential for cardiovascular cell lineage specification. Potentiation of NO signaling with small therapeutic molecules restored cardiogenesis in vitro and may identify a potential therapeutic target for patients affected by functionally compromised NOTCH1 variants. Stem Cells 2017;35:1106-1119.
© 2017 The Authors STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Entities:  

Keywords:  Cardiac; Developmental biology; Differentiation; Drug target; Hypoplastic left heart syndrome; NOTCH1; Pluripotent stem cells

Mesh:

Substances:

Year:  2017        PMID: 28142228     DOI: 10.1002/stem.2582

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  16 in total

Review 1.  HiPS-Cardiac Trilineage Cell Generation and Transplantation: a Novel Therapy for Myocardial Infarction.

Authors:  Ampadu O Jackson; Huifang Tang; Kai Yin
Journal:  J Cardiovasc Transl Res       Date:  2019-05-31       Impact factor: 4.132

Review 2.  Delving into the Molecular World of Single Ventricle Congenital Heart Disease.

Authors:  Zhiyun Yu; Nicole Min Qian Pek; Mingxia Gu
Journal:  Curr Cardiol Rep       Date:  2022-02-26       Impact factor: 2.931

Review 3.  Hypoplastic left heart syndrome (HLHS): molecular pathogenesis and emerging drug targets for cardiac repair and regeneration.

Authors:  Anthony T Bejjani; Neil Wary; Mingxia Gu
Journal:  Expert Opin Ther Targets       Date:  2021-09-15       Impact factor: 6.797

Review 4.  Probing single ventricle heart defects with patient-derived induced pluripotent stem cells and emerging technologies.

Authors:  Bailey Hall; Matthew Alonzo; Karen Texter; Vidu Garg; Ming-Tao Zhao
Journal:  Birth Defects Res       Date:  2022-02-24       Impact factor: 2.661

Review 5.  Translational potential of hiPSCs in predictive modeling of heart development and disease.

Authors:  Corrin Mansfield; Ming-Tao Zhao; Madhumita Basu
Journal:  Birth Defects Res       Date:  2022-03-09       Impact factor: 2.661

6.  Uncompensated mitochondrial oxidative stress underlies heart failure in an iPSC-derived model of congenital heart disease.

Authors:  Xinxiu Xu; Kang Jin; Abha S Bais; Wenjuan Zhu; Hisato Yagi; Timothy N Feinstein; Phong K Nguyen; Joseph D Criscione; Xiaoqin Liu; Gisela Beutner; Kalyani B Karunakaran; Krithika S Rao; Haoting He; Phillip Adams; Catherine K Kuo; Dennis Kostka; Gloria S Pryhuber; Sruti Shiva; Madhavi K Ganapathiraju; George A Porter; Jiuann-Huey Ivy Lin; Bruce Aronow; Cecilia W Lo
Journal:  Cell Stem Cell       Date:  2022-04-07       Impact factor: 25.269

7.  Intrinsic Endocardial Defects Contribute to Hypoplastic Left Heart Syndrome.

Authors:  Yifei Miao; Lei Tian; Marcy Martin; Sharon L Paige; Francisco X Galdos; Jibiao Li; Alyssa Klein; Hao Zhang; Ning Ma; Yuning Wei; Maria Stewart; Soah Lee; Jan-Renier Moonen; Bing Zhang; Paul Grossfeld; Seema Mital; David Chitayat; Joseph C Wu; Marlene Rabinovitch; Timothy J Nelson; Shuyi Nie; Sean M Wu; Mingxia Gu
Journal:  Cell Stem Cell       Date:  2020-08-17       Impact factor: 24.633

Review 8.  In Vivo and In Vitro Genetic Models of Congenital Heart Disease.

Authors:  Uddalak Majumdar; Jun Yasuhara; Vidu Garg
Journal:  Cold Spring Harb Perspect Biol       Date:  2021-04-01       Impact factor: 10.005

9.  Contractility of Induced Pluripotent Stem Cell-Cardiomyocytes With an MYH6 Head Domain Variant Associated With Hypoplastic Left Heart Syndrome.

Authors:  Min-Su Kim; Brandon Fleres; Jerrell Lovett; Melissa Anfinson; Sai Suma K Samudrala; Lauren J Kelly; Laura E Teigen; Matthew Cavanaugh; Maribel Marquez; Aron M Geurts; John W Lough; Michael E Mitchell; Robert H Fitts; Aoy Tomita-Mitchell
Journal:  Front Cell Dev Biol       Date:  2020-06-23

10.  Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome.

Authors:  Jeanne L Theis; Georg Vogler; Maria A Missinato; Timothy J Nelson; Timothy M Olson; Alexandre R Colas; Rolf Bodmer; Xing Li; Tanja Nielsen; Xin-Xin I Zeng; Almudena Martinez-Fernandez; Stanley M Walls; Anaïs Kervadec; James N Kezos; Katja Birker; Jared M Evans; Megan M O'Byrne; Zachary C Fogarty; André Terzic; Paul Grossfeld; Karen Ocorr
Journal:  Elife       Date:  2020-10-02       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.